Abstract
Background: We evaluated a standardized interferon-γ (IFN-γ) release assay (IGRA) for detection of T-cell immune response after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or vaccination.
Methods: This prospective study included patients with coronavirus disease 2019 (COVID-19) with different severity of illness and follow-up (FU), vaccinated subjects, and healthy unvaccinated persons. SARS-CoV-2 T-cell response was measured using a specific quantitative IGRA in whole blood (Euroimmun, Germany) and TrimericS-IgG and neutralizing antibodies with validated serological platforms. Positivity of reverse transcription-polymerase chain reaction or vaccination was considered as the reference standard.
Results: A total of 239 individuals were included (152 convalescent, 54 vaccinated, and 33 uninfected unvaccinated). Overall sensitivity, specificity, and positive- and negative-predictive values (95% confidence interval) of the IGRA were 81.1% (74.9-86%), 90.9% (74.5-97.6%), 98.2% (94.5-99.5%), and 43.5% (31.8-55.9%), respectively. All vaccinated SARS-CoV-2-naive subjects had positive IGRA at 3 months. In convalescent subjects the magnitude of IFN-γ responses and IGRA accuracy varied according to disease severity and duration of FU, with the best performance in patients with severe COVID-19 at 3 months and the worst in those with mild disease at 12 months. The greatest contribution of IGRA to serological tests was observed in patients with mild disease and long-term FU (incremental difference, 30.4%).
Conclusions: The IGRA was a reliable method of quantifying T-cell response after SARS-COV-2 infection or vaccination. In convalescent patients, the sensitivity is largely dependent on disease severity and time since primary infection. The assay is more likely to add clinical value to serology in patients with mild infections.
Keywords: 19; 2; COVID; CoV; IGRA; SARS; T; cell response; interferon; γ release assay.
【저자키워드】 SARS, interferon, COVID, CoV, 19, 2, IGRA, T, cell response, γ release assay., 【초록키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, neutralizing antibody, serological test, SARS-CoV-2, Coronavirus disease 2019, coronavirus, immune response, vaccination, severe COVID-19, Neutralizing antibodies, serology, SARS-COV-2 infection, severity, disease severity, T-cell Response, Prospective Study, Infection, interferon, severe acute respiratory syndrome Coronavirus, polymerase chain reaction, sensitivity, specificity, Convalescent patients, Serological tests, Accuracy, Whole blood, Germany, Patient, reverse transcription, Follow-up, T-cell, respiratory, convalescent, serological, Euroimmun, Quantitative, reference standard, IFN-γ, Mild disease, Primary infection, Reverse transcription-polymerase chain reaction, best, Chain Reaction, severity of illness, interferon-γ, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, 95% confidence interval, subject, individual, positive, mild infections, uninfected, Cell, IFN-γ responses, was measured, healthy, evaluated, subjects, dependent on, magnitude, IFN-γ response, with mild disease, 【제목키워드】 SARS-CoV-2, Release, detection, coronavirus 2, clinical, response, performance, simple,